|
(Health-NewsWire.Net, August 09, 2024 ) The Targeted Protein Degradation Market is estimated to reach over USD 2.65 Bn by 2031, exhibiting a CAGR of 26.3% during the forecast period.
Targeted protein degradation (TPD) seeks to completely remove specific proteins from the cell, rather than merely inhibiting their activity. This approach can potentially provide more effective and sustained treatment outcomes for various diseases by thoroughly eliminating disease-causing proteins. By leveraging the cell's natural degradation pathways, TPD can address issues that traditional therapies cannot, such as drug resistance and incomplete inhibition. Consequently, this innovative strategy holds significant promise for advancing the treatment of conditions like cancer, neurodegenerative diseases, and infectious diseases, offering new hope for patients with previously intractable conditions.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2530
Targeted protein degradation (TPD) seeks to completely remove specific proteins from the cell, rather than merely inhibiting their activity. This approach can potentially provide more effective and sustained treatment outcomes for various diseases by thoroughly eliminating disease-causing proteins. By leveraging the cell's natural degradation pathways, TPD can address issues that traditional therapies cannot, such as drug resistance and incomplete inhibition. Improved techniques in drug delivery, high-throughput screening, and protein engineering are enhancing the efficacy and specificity of TPD therapies.
List of Prominent Players in the Targeted Protein Degradation Market:
• Arvinas
• Bristol-Myers Squibb
• C4 Therapeutics
• Loxo Oncology
• Olema Oncology
• Radius Health
• AstraZeneca
• Roche
• BeiGene
• InnoCare Pharma
• Kangpu Biopharmaceuticals
• Kintor Pharmaceuticals
• Medivir
• Monte Rosa Therapeutics
• Ranok Therapeutics
• Sanofi
• Zentalis Pharmaceuticals
• Eisai Therapeutics
Market Dynamics:
Drivers:
The promising potential of TPD to transform disease treatment is attracting significant interest and investment from venture capitalists and pharmaceutical companies. Positive outcomes from ongoing research and clinical trials are boosting confidence in TPD therapies, accelerating their development. Additionally, partnerships between pharmaceutical companies, biotech firms, and academic institutions are fostering innovation and expanding the reach of TPD research and applications. The global increase in diseases such as cancer and neurodegenerative disorders is creating a demand for innovative therapies, making TPD a valuable approach.
Challenges:
Developing PROTACs and other TPD molecules is technically complex, requiring precise design to ensure efficacy and selectivity. Potential off-target effects and toxicity are significant concerns, necessitating thorough evaluation in preclinical and clinical trials. Additionally, high research and development costs, along with the need for extensive clinical trials, can be prohibitive for some companies.
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02
Regional Trends:
There's a growing focus on personalized medicine in North America, with an emphasis on developing targeted therapies for specific patient populations. TPD aligns well with this trend, offering the potential for more precise and effective treatments. The region boasts a well-established and well-funded pharmaceutical industry with a strong track record of innovation in drug discovery. These companies have the resources and expertise to invest heavily in TPD research and development, propelling the market forward.
Recent Developments:
• In April 2024, Arvinas, Inc., announced that it has signed a strategic license agreement with Novartis for the global development and commercialization of ARV-766, Arvinas' second-generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer. is a clinical-stage biotechnology company developing a new class of drugs based on targeted protein degradation. An asset purchase agreement for the sale of Arvinas' preclinical AR-V7 program to Novartis is also a part of the transaction.
• In September 2023, Bristol Myers Squibb is hosting a Research and Development (R&D) Day in New York to discuss the company's R&D capabilities and strategy and provide information about its strong pipeline that supports sustainable long-term growth. The company's leadership team will also showcase its improved R&D framework and unique research platforms, which are anticipated to provide exceptional productivity that produces top-notch early-stage candidates and noticeably shortens R&D timelines.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2530
Segmentation of Targeted Protein Degradation Market.
Global Targeted Protein Degradation Market –By Type of Degrader
• SERD
• PROTAC
• Molecular Glue
Global Targeted Protein Degradation Market – Target Indication
• Breast Cancer
• Multiple Myeloma
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2530
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Insight Ace Analytics
Diana D’souza
+917972967118
diana.dsouza@insightaceanalytics.com
Source: EmailWire.Com 
|
